Attached files
| file | filename |
|---|---|
| EX-99.1 - ADDITIONAL EXHIBITS - Cellular Biomedicine Group, Inc. | cbmg_ex991.htm |
| 8-K - PRIMARY DOCUMENT - Cellular Biomedicine Group, Inc. | cbmg_8k.htm |
Exhibit
99.2
Cellular Biomedicine Group to Present at Chinese Biopharmaceutical
Association-USA Annual Conference
NEW YORK, NY and SHANGHAI, China, August 26, 2020 –
Cellular Biomedicine Group, Inc.
(NASDAQ: CBMG) (“CBMG” or the “Company”), a
biopharmaceutical firm engaged in the drug development of
immunotherapies for cancer and stem cell therapies for degenerative
diseases, is scheduled for a presentation at the
25th
Annual Conference of the Chinese
Biopharmaceutical Association-USA to be held online August 29-30,
2020.
|
Presentation Title:
|
“Building
a Competitive Cell Therapy Pipeline for Cancer
Patients”
|
|
Session:
|
Cell and Gene Therapy
|
|
Speaker:
|
Dr. Yihong Yao, Chief Scientific Officer, CBMG
|
|
Date:
|
Sunday, August 30, 2020
|
|
Time:
|
10:10 a.m.to 10:35 a.m. EDT
|
|
Location:
|
Broadcast virtually from Rockville, MD
|
|
Website:
|
https://www.cba-usa.org/content/2020-cba-annual-conference
|
About Cellular Biomedicine Group, Inc.
Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) develops
proprietary cell therapies for the treatment of cancer and
degenerative diseases. The company conducts immuno-oncology and
stem cell clinical trials in China using products from its
integrated GMP laboratory. The Company’s GMP facilities in
China, consisting of twelve independent cell production lines, are
designed and managed according to both China and U.S. GMP
standards. Its Shanghai facility includes a “Joint Laboratory
of Cell Therapy” with GE Healthcare and a “Joint Cell
Therapy Technology Innovation and Application Center” with
Thermo Fisher Scientific. These partnerships focus on improving
manufacturing processes for cell therapies. CBMG currently has
ongoing CAR-T Phase I clinical trials in China. The China NMPA
(formerly CFDA) approved the Company’s IND application for a
Phase II trial for AlloJoin®, CBMG’s
“Off-the-Shelf” allogenic haMPC therapy for the
treatment of Knee Osteoarthritis (KOA), and has accepted the
Company’s IND application for a Phase II trial for
ReJoin® autologous haMPC therapy for the treatment of KOA. The
NMPA has also accepted CBMG’s dossier for an IND application
for clinical trials of anti-BCMA CAR-T. CBMG is included in the
broad-market Russell 3000® Index the small-cap Russell
2000® Index and the Loncar China BioPharma index. To learn
more about CBMG, please
visit www.cellbiomedgroup.com.
Company Contact:
Derrick C. Li
Head of Strategy and Investor Relations, CBMG
Phone: 917-717-0994
Email: derrick.li@cellbiomedgroup.com